Turning tumors into local immunotherapy factories is among the strategies highlighted in preclinical cell, gene, and mRNA ...

Alethio wants to lower platelet counts in essential thrombocythemia and shrink the malignant clone that drives their ...

Genetic studies continue to strengthen the case for targeting microglia in Alzheimer’s disease. The harder task is ...

Building better biological AI models requires more than simply generating more data. Four initiatives launched or expanded in ...

FDA approved the first plasmid DNA-based immunotherapy in October, granting accelerated approval to Inovio’s Voceryq ...

Caspian is developing an oral menin inhibitor to regenerate patients’ own pancreatic beta cells, with plans to begin testing ...

The political action committees of the 10 largest drugmakers by 2025 global pharmaceutical sales, along with PhRMA and BIO, directed nearly all their ...

A single trading day offers limited evidence, but Friday’s sharp divergence between tech and large-cap biopharma stocks suggests the latter could ...

Washington spends enormous energy scrutinizing the policy positions of FDA commissioner nominees. But does it pay enough attention to whether they can ...

FDA has at least eleven PDUFA dates on its November calendar, 10 of which are for new products. First up is PD-1 x VEGF ...